Company / EPS (Diluted)
CG Oncology, Inc. EPS (Diluted) History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$2.08
FY2025
5-year range
-$15.65 / -$1.41
FY2023-FY2025
Trend
-47.5%
vs FY2024
Sector context
#127 of 204
Health Care
What the data says
At $-2.08, CG Oncology, Inc.'s eps (diluted) ranks #127 of 204 in the Health Care sector. Improved from $-15.65 to $-2.08 over the past 2 years.
Based on SEC 10-K filings.
-2.08 in FY2025.
Improved from $-15.65 to $-2.08 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#127 of 204 in Health CareTop 62% of 204This company -$2.08 Sector average -$1.30
▼
-59.6% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 47.5% year-over-year.
- Ranks #127 out of 204 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 8.02 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$2.08 | -47.5% |
| FY2024 | -$1.41 | +91.0% |
| FY2023 | -$15.65 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026